Human osteocalcin: a strong promoter for nitric oxide synthase gene therapy, with specificity for hormone refractory

Helen O McCarthy1, Jonathan A Coulter, Jenny Worthington

  • 1School of Pharmacy, McClay Research Centre, Queen's University, Lisburn Road, Belfast, Northern Ireland, UK. h.mccarthy@qub.ac.uk

Abstract

Insights

This study introduces a novel gene therapy approach for hormone refractory prostate cancer using the human osteocalcin promoter to control nitric oxide synthase expression. The therapy demonstrated targeted cell specificity and reduced cancer cell survival in androgen-independent prostate cancer cells.

Area of Science:

  • Oncology
  • Gene Therapy
  • Molecular Biology

Background:

  • Gene therapy is a promising strategy for hormone refractory prostate cancer (HRPC).
  • The human osteocalcin (hOC) promoter was investigated for controlling transgene expression.
  • Inducible nitric oxide synthase (iNOS) is a target for cancer therapy.

Purpose of the Study:

  • To evaluate the efficacy of the hOC promoter for inducible nitric oxide synthase (iNOS) gene therapy in HRPC.
  • To assess the target cell specificity and cytotoxicity of hOC/iNOS in prostate cancer models.
  • To compare hOC/iNOS with constitutively driven iNOS expression.

Main Methods:

  • Human prostate cancer cell lines (PC3, DU145, LNCaP) and control cells were transfected with hOC/iNOS or CMV/iNOS plasmids.
  • Transfection was achieved using a cationic lipid vector.
  • Assays included Western blotting, Greiss test for nitrite measurement, and clonogenic assays.

Main Results:

  • hOC/iNOS transfection increased iNOS protein and nitrite levels in androgen-independent PC3 and DU145 cells.
  • No significant cytotoxicity was observed in androgen-dependent LNCaP cells or non-prostate cell lines.
  • Cell survival was significantly reduced (to 10-20%) in PC3 and DU145 cells with both hOC/iNOS and CMV/iNOS.

Conclusions:

  • The hOC promoter enables tumor-type specific transgene activation of iNOS in androgen-independent prostate cancer cells.
  • Nitric oxide generation with hOC/iNOS is comparable to constitutively driven iNOS.
  • This study provides a foundation for developing hOC/iNOS gene therapy for HRPC.

Related Concept Videos

Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Hormones and Bone Tissue01:17

Hormones and Bone Tissue

The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Regulation of Hormone Secretion01:19

Regulation of Hormone Secretion

Regulation of hormone secretion is a finely tuned orchestration driven by various types of stimuli, encompassing neural, humoral, and hormonal signals. Environmental cues instigate neural stimuli, where action potentials traverse nerve fibers to reach their designated targets. An illustrative scenario is the body's response to stress, wherein the sympathetic nervous system releases epinephrine from the adrenal glands, inducing the well-known 'fight or flight' reaction.
Humoral stimuli,...
Paracrine Signaling01:21

Paracrine Signaling

Paracrine signaling allows cells to communicate with their immediate neighbors via secretion of signaling molecules. Such a signal can only trigger a response in nearby target cells because the signal molecules degrade quickly or are inactivated if not taken up. Prominent examples of paracrine signaling include nitric oxide signaling in blood vessels, synaptic signaling of neurons, the blood clotting system, tissue repair/wound healing, and local allergic skin reactions. Nitric oxide as a...